PCSK9 and early-onset autosomal dominant Alzheimer disease: Given the small number of ε4/ε4 carriers in this sample, future research is needed to evaluate the effectiveness of PCSK9 inhibitors to reduce the risk of cognitive decline in those most at risk for Alzheimer’s disease.